MLMatthew Shane Loop

Matthew Shane Loop

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew Shane Loop has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacist-led Transitions of Care Intervention to Address Infectious Disease Tests Pending at Discharge (TPAD)

    by Elizabeth W Covington, Matthew Shane Loop, Jieun Park, Leborah Lee, Mary Bowman, Sarah Grace Gunter

    Background: Infectious disease test results frequently finalize after hospital discharge, and many are clinically actionable. Standardized workflows for reviewing these results remain limited. Although pharmacist-led culture follow-up is well established in emergency departments, evidence evaluating inpatient transitions-of-care models is sparse. This study assessed the impact of a pharmacist-led service on outpatient antimicrobial appropriateness and clinical outcomes. Methods: We conducted a single-center, retrospective pre–post study at a community hospital comparing patients discharged with pending infectious disease test results before and after service implementation. The intervention included thrice-weekly review of finalized results, clinical assessment, prescriber communication, outpatient prescription changes, and patient counseling. The primary outcome was appropriate outpatient antimicrobial therapy 7 days after discharge. Secondary outcomes included time to appropriate therapy among patients requiring prescription modification and 30-day infection-related outcomes. Multivariable logistic regression adjusted for urine culture source, discharge service, and inpatient infectious diseases consultation. Time-to-therapy analyses used Kaplan–Meier and Cox proportional hazards. Results: Among 191 patients (93 preintervention; 98 postintervention), appropriate antimicrobial therapy at 7 days increased from 69% to 92%. Adjusted analyses showed a 21.3% higher predicted probability of appropriate therapy (95% CI, 10.6–32.0). Among patients requiring prescription changes (n = 63), median time to appropriate therapy improved from 7 to 4 days, with a 5-fold higher rate of achieving appropriate therapy (hazard ratio, 5.09; 95% CI, 2.13–12.18). Thirty-day outcomes were similar between groups. Conclusions: A pharmacist-led service improved antimicrobial appropriateness and accelerated transitions to appropriate therapy, supporting pharmacist-driven follow-up as an effective stewardship strategy.

  • Open Access

    Dosing trajectories of antihypertensive agents among preterm neonates: A retrospective, cross-sectional analysis

    by Mary-Carty Pittman, Alejandro D. Perez, Kaniz Afroz Tanni, Keia R. Sanderson, Jieun Park, Daniel I. Feig, Matthew M. Laughon, Matthew Shane Loop

    Introduction: Preterm infants are at increased risk for hypertension due to incomplete organ development. With no established guidelines for treating hypertension in this population, clinicians rely on their experience, and little is known regarding those treatment decisions. This study described dosing trajectories for the three most common antihypertensive agents in preterm infants. Methods: This retrospective, cross-sectional study examined preterm neonates (gestational age at birth < 37 weeks, postmenstrual age < 44 weeks) treated with antihypertensive medications at the University of Alabama at Birmingham (UAB) Medical Center. The study identified the three most common antihypertensive agents and identified common dosing patterns over time using the functional K-means algorithm. We then compared demographic and clinical information across these clusters. Results: The study included 87 patients across 93 visits. The three most common antihypertensive agents were propranolol (61%), captopril (8.8%), and esmolol (12%). Median treatment durations were 292 hours for propranolol, 186 hours for captopril, and 68 hours for esmolol. Propranolol was often initiated at a dose that was maintained with few dosing changes. Patients needing higher doses of propranolol were generally younger gestational age and spent longer in the hospital. Captopril doses started low and increased over time, likely due to safety concerns. Esmolol showed the most variable dosing trajectories. Conclusions: Propranolol is often initiated at a target dose and maintained with less titration, while both captopril and esmolol are titrated more often. Younger gestational age patients typically required higher doses of propranolol.

  • Open Access

    Comparative study on the time trends of antimicrobial resistance at animal and human hospitals in a shared community

    by Mackenzie Blackstock, Jieun Park, Matthew Shane Loop, Melanie Hyte, Andrea Perkins, Sarah Grace Gunter, Laura Matthews, Laura Huber


  • Open Access

    Sequence of antihypertensive medications used in preterm infants with hypertension: A cross-sectional study

    by Alejandro D. Perez, Mary-Carty Pittman, Kaniz Afroz Tanni, Keia R. Sanderson, Jieun Park, Daniel I. Feig, Matthew M. Laughon, Matthew Shane Loop

    Background: Hypertension in preterm infants can result in life-threatening outcomes. However, there is limited evidence to guide the pharmacologic management of hypertension in preterm infants. Without population-level studies of the pharmacologic strategies that clinicians currently employ for hypertension in preterm infants, studies investigating the benefits and risks of these strategies cannot be performed. Methods: A retrospective, cross-sectional study was conducted at a single academic medical centerto determine the most prevalent antihypertensive medication used for first-line, second-line, and adjunctive pharmacologic management among preterm infants with hypertension. The study sample included patients with a postnatal age less than 1 year at hospital discharge, gestational age at birth less than 37 weeks, and treated with an antihypertensive medication between July 2010 and December 2022. The prevalence of each antihypertensive medication used for each stage of pharmacologic management was estimated, and prevalences were compared using prevalence ratios. Bayesian multinomial regression was used to estimate prevalence ratios and 95% credible intervals (CIs). Results: Out of 751 possibly eligible patient encounters obtained, 134 encounters were identified across 120 patients that met the inclusion criteria. Second-line and adjunctive pharmacologic management were used in 6 and 12 encounters, respectively. Propranolol had the highest prevalence for each stage of pharmacologic management: 61% for first-line (95% CI: 53-69%); 40% for second-line (95% CI: 14-70%); and 47% for adjunctive pharmacologic management (95% CI: 24-72%). As a first-line pharmacologic management, propranolol was 4.8 times (95% CI: 2.9-7.7) as prevalent as the second most prevalent medication (captopril). Conclusion: In a large academic hospital, propranolol was the most commonly used medication for first-line antihypertensive pharmacologic management among preterm infants. The most prevalent medication used for second-line and adjunctive pharmacologic management was inconclusive.

  • Should regression calibration or multiple imputation be used when calibrating different devices in a longitudinal study?

    by Matthew Shane Loop, Sarah C Lotspeich, Tanya P Garcia, Michelle L Meyer

    In longitudinal studies, the devices used to measure exposures can change from visit to visit. Calibration studies, wherein a subset of participants is measured using both devices at follow-up, may be used to assess between-device differences (ie, errors). Then, statistical methods are needed to adjust for between-device differences and the missing measurement data that often appear in calibration studies. Regression calibration and multiple imputation are two possible methods. We compared both methods in linear regression with a simulation study, considering various real-world scenarios for a longitudinal study of pulse wave velocity. Regression calibration and multiple imputation were both essentially unbiased, but correctly estimating the standard errors posed challenges. Multiple imputation with predicted mean matching produced close agreement with the empirical standard error. Fully stochastic multiple imputation underestimated the standard error by up to 50%, and regression calibration with bootstrapped standard errors performed slightly better than fully stochastic multiple imputation. Regression calibration was slightly more efficient than either multiple imputation method. The results suggest use of multiple imputation with predictive mean matching over fully stochastic imputation or regression calibration in longitudinal studies where a new device at follow-up might be error-prone compared to the device used at baseline.


  • Open Access

    Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD

    by William A. Murphy, Anna Mae Diehl, Matthew Shane Loop, Dong Fu, Cynthia D. Guy, Manal F. Abdelmalek, Georgia Sofia Karachaliou, Noora Sjöstedt, Sibylle Neuhoff, Paavo Honkakoski, et al.

    Background: NAFLD is highly prevalent with limited treatment options. Bile acids (BAs) increase in the systemic circulation and liver during NAFLD progression. Changes in plasma membrane localization and zonal distribution of BA transporters can influence transport function and BA homeostasis. However, a thorough characterization of how NAFLD influences these factors is currently lacking. This study aimed to evaluate the impact of NAFLD and the accompanying histologic features on the functional capacity of key hepatocyte BA transporters across zonal regions in human liver biopsies. Methods: A novel machine learning image classification approach was used to quantify relative zonal abundance and plasma membrane localization of BA transporters (bile salt export pump [BSEP], sodium-taurocholate cotransporting polypeptide, organic anion transporting polypeptide [OATP] 1B1 and OATP1B3) in non-diseased (n = 10), NAFL (n = 9), and NASH (n = 11) liver biopsies. Based on these data, membrane-localized zonal abundance (MZA) measures were developed to estimate transporter functional capacity. Results: NAFLD diagnosis and histologic scoring were associated with changes in transporter membrane localization and zonation. Increased periportal BSEPMZA (mean proportional difference compared to non-diseased liver of 0.090) and decreased pericentral BSEPMZA (−0.065) were observed with NASH and also in biopsies with higher histologic scores. Compared to Non-diseased Liver, periportal OATP1B3MZA was increased in NAFL (0.041) and NASH (0.047). Grade 2 steatosis (mean proportional difference of 0.043 when compared to grade 0) and grade 1 lobular inflammation (0.043) were associated with increased periportal OATP1B3MZA. Conclusions: These findings provide novel mechanistic insight into specific transporter alterations that impact BA homeostasis in NAFLD. Changes in BSEPMZA likely contribute to altered BA disposition and pericentral microcholestasis previously reported in some patients with NAFLD. BSEPMZA assessment could inform future development and optimization of NASH-related pharmacotherapies.


  • Open Access

    Use of Real‐World Data and Physiologically‐Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity

    by Jacqueline G. Gerhart, Fernando O. Carreño, Matthew Shane Loop, Craig R. Lee, Andrea N. Edginton, Jaydeep Sinha, Karan R. Kumar, Carl M. Kirkpatrick, Christoph P. Hornik, Daniel Gonzalez, et al.

    Dosing guidance for children with obesity is often unknown despite the fact that nearly 20% of US children are classified as obese. Enoxaparin, a commonly prescribed low‐molecular‐weight heparin, is dosed based on body weight irrespective of obesity status to achieve maximum concentration within a narrow therapeutic or prophylactic target range. However, whether children with and without obesity experience equivalent enoxaparin exposure remains unclear. To address this clinical question, 2,825 anti–activated factor X (anti‐Xa) surrogate concentrations were collected from the electronic health records of 596 children, including those with obesity. Using linear mixed‐effects regression models, we observed that 4‐hour anti‐Xa concentrations were statistically significantly different in children with and without obesity, even for children with the same absolute dose (P = 0.004). To further mechanistically explore obesity‐associated differences in anti‐Xa concentration, a pediatric physiologically‐based pharmacokinetic (PBPK) model was developed in adults, and then scaled to children with and without obesity. This PBPK model incorporated binding of enoxaparin to antithrombin to form anti‐Xa and elimination via heparinase‐mediated metabolism and glomerular filtration. Following scaling, the PBPK model predicted real‐world pediatric concentrations well, with an average fold error (standard deviation of the fold error) of 0.82 (0.23) and 0.87 (0.26) in children with and without obesity, respectively. PBPK model simulations revealed that children with obesity have at most 20% higher 4‐hour anti‐Xa concentrations under recommended, total body weight–based dosing compared to children without obesity owing to reduced weight‐normalized clearance. Enoxaparin exposure was better matched across age groups and obesity status using fat‐free mass weight‐based dosing.


  • The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions

    by Ian R. Mulrenin, Julian E. Garcia, Muluneh M. Fashe, Matthew Shane Loop, Melissa A. Daubert, Rachel Peragallo Urrutia, Craig R. Lee

    Hypertensive disorders of pregnancy (HDP) are rising in prevalence, and increase risk of adverse maternal and fetal outcomes. Physiologic changes occur during pregnancy that alter drug pharmacokine...


  • POSTPARTUM BLOOD PRESSURE SCREENING IN WOMEN WITH HYPERTENSIVE DISORDERS OF PREGNANCY

    by Melissa A. Daubert, Amanda Stebbins, Rachel Urrutia, Karen Chiswell, Matthew Loop, Ceshae Harding, Thomas Price, Paula Miller, Tracy Wang

  • Open Access

    Rapid report on estimating incidence from cross-sectional data

    by Justin B. DeMonte, Anne M. Neilan, Matthew S. Loop, Andrea L. Ciaranello, Michael G. Hudgens